Print Page | Close Page

 

 

VIR Biotechnology

Address: 499 Illinois Street, Suite 500, San Francisco, California. CA 94158
 
Country: USA
 
Sectors: Proprietary Research & Manufacture
 
Website: https://www.vir.bio
 
- - -
 

About Us

At Vir Biotechnology, Inc., we leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in chronic hepatitis delta are complemented by strategic programs in oncology. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients. Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and our protease-releasable masking platform in infectious disease and cancer. Explore our full pipeline here: https://bit.ly/3tr7FPm It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir Bio's recruiting process: https://bit.ly/461EgJN

 
- - -
 

Sectors

  • Proprietary Research & Manufacture
 
 
- - -
 

Categories

  • Biotechnology
  • Biologics
  • BioPharmaceuticals
  • Antibodies-monoclonals
 
  • Immunology
  • Immunotherapy
  • Anti-Infection Products
  • Anti-Virals
 
- - -
 

News

 
26th February 2026
 

Astellas and Vir Biotechnology Announce Global Strategic Collaboration

 

Vir Biotechnology will receive $335M in upfront and near-term milestone payments, will splitĀ U.S. profit/loss equally with Astellas (50/50), and is eligible to receive up to an additional $1.37B in development, regulatory and sales milestones, along with tiered, double-digit royalties on ex-U.S. net sales -

 
- - -
 
Printed: 15-Apr-2026 at 22:36:30 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com